A Study to Compare Iberdomide Maintenance Versus Lenalidomide Maintenance Therapy Following Autologous Stem Cell Transplant in Participants With Newly Diagnosed Multiple Myeloma

Open to people ages 18 years and up

• Confirmed diagnosis of symptomatic multiple myeloma (MM)
• Eastern Cooperative Oncology Group performance status (ECOG) score of 0, 1, or 2
• Received 3 to 6 cycles of an induction therapy that includes a proteasome inhibitor (PI) and immunomodulatory (IMiD) [eg, bortezomib thalidomide and dexamethasone (VTd), lenalidomide, bortezomib and dexamethasone (RVd)] with or without a CD38 monoclonal antibody, or Velcade® (bortezomib), cyclophosphamide, dexamethasone (VCd), and followed by a single or tandem autologous stem cell transplantation (ASCT). Post-stem cell transplant consolidation is permitted
• Participants within 12 months from initiation of induction therapy who achieved at least a partial response (PR) after autologous stem cell transplantation (ASCT) with or without consolidation, according to International Myeloma Working Group (IMWG 2016) criteria

• Progressive disease or clinical relapse (as defined by IMWG response criteria) following ASCT with or without consolidation or is not responsive to primary therapy
• Smoldering myeloma, solitary plasmacytoma or nonsecretory myeloma
• Known central nervous system/meningeal involvement of MM

• Prior history of malignancies, other than MM, unless the participant has been free of the disease for ≥ 5 years

  Other protocol-defined inclusion/exclusion criteria apply